Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements ...Middle East

Results continue to support evidence for safety, tolerability, clinical efficacy, and biomarker improvements of DT-DEC01 At 6 months treated patients achieved mean significant increase in motor unit potential (MUP) levels of up to 200% of baseline, as measured by electromyography...

Hence then, the article about dystrogen therapeutics investigational chimeric cell therapy dt dec01 for duchenne muscular dystrophy demonstrates clinically significant functional and biomarker improvements was published today ( Monday 26/09/2022 - 05:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements )

Also on site :

• My Big Family Once Formed the Backbone of My Life. Then, We Discovered My Sister’s Horrific Actions. Now Nothing Is the Same.
• Royal Caribbean Extends Pause at Private Caribbean Resort Through 2026—Here’s What Cruisers Are Getting Instead
• HomeGoods' Gorgeous New Valentine's Glassware Has Shoppers Saying: 'I Need It All'